Harrow Health Inc (HROW) saw its shares tumble 13.91% in after-hours trading on Monday following the release of its third-quarter financial results for 2025. The pharmaceutical company's earnings and revenue fell short of analyst expectations, triggering a sell-off among investors.

The company reported an adjusted earnings per share (EPS) of $(0.12), significantly missing the analyst estimate of $0.26. Revenue for the quarter came in at $71.638 million, also falling short of the projected $73.705 million. These disappointing figures led to an immediate drop in Harrow's stock price, with shares initially declining 11.1% when the results were first announced.

Despite the overall negative reception, Harrow Health did report some positive metrics. The company's core gross margin stood at a robust 81%, indicating strong profitability for its primary product lines. However, the overall gross margin was lower at 75%, suggesting some pressure on the company's broader product portfolio. The discrepancy between core and overall performance may raise questions among investors about the company's product mix and operational efficiency.